Choose Your News
Loading...
Thumbnail
In spite of concerns regarding lead drug Ocaliva, Intercept's 46% plunge last year might offer an intriguing buying opportunity. [Read More]
Thumbnail
There will soon be a new country exporting dried cannabis for medicinal purposes. [Read More]
Thumbnail
Teva threw everything but the kitchen sink at its shareholders last year, but the future is beginning to look brighter. [Read More]
Thumbnail
What happened... [Read More]
Thumbnail
A 104% gain last year wouldn't have been possible without lead drug Cabometyx. [Read More]
Thumbnail
Sure, cryptocurrencies have been getting most of the glory of late, but few if any publicly traded stocks have outperformed like marijuana stocks have over... [Read More]
Thumbnail
Historically, no asset has been a greater source of wealth creation than the stock market. Throughout its history, stocks have returned an average of. [Read More]
Thumbnail
Bitcoin's dominance is about as low as it's ever been suggesting that the valuations of other virtual coins are growing at a much quicker pace... [Read More]
Wall Street rewards the embattled Valeant after the company met numerous goals last year. [Read More]
Uncertainty regarding Geron's partnership with Johnson & Johnson takes shareholders for a wild ride. [Read More]
What happened... [Read More]
These prominent drug developers look to be enticing buys this month. [Read More]
Plans to "trim the fat" have Wall Street and investors excited. [Read More]
The North American marijuana industry is budding in a big way. Sure, that may sound corny, but expected legal sales growth of 26% per year... [Read More]
Historically, the stock market has been the best creator of long-term wealth. Though it's undergone numerous corrections and bear markets, it's still. [Read More]
Cryptocurrencies absolutely kicked butt last year, leaving traditional equities, like the stock market, eating their dust.At the very end of 2016,. [Read More]
As forecasts predict air travel will increase by 65 percent over the next two decades, the need to upgrade America's antiquated air traffic control system... [Read More]
So much for helping out middle-income retired workers. [Read More]
Valeant took another step forward on its road to redemption, but it still has a long walk ahead. [Read More]
What happened... [Read More]
Loading...
Preview